

Kathleen K Christians

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1228664/publications.pdf>

Version: 2024-02-01

93
papers

1,512
citations

331670

21
h-index

330143

37
g-index

94
all docs

94
docs citations

94
times ranked

2240
citing authors

#	ARTICLE	IF	CITATIONS
1	Neoadjuvant FOLFIRINOX for Borderline Resectable Pancreas Cancer: A New Treatment Paradigm?. <i>Oncologist</i> , 2014, 19, 266-274.	3.7	183
2	Survival of patients with resectable pancreatic cancer who received neoadjuvant therapy. <i>Surgery</i> , 2016, 159, 893-900.	1.9	114
3	Arterial resection at the time of pancreatectomy for cancer. <i>Surgery</i> , 2014, 155, 919-926.	1.9	94
4	Transarterial chemoembolization in hepatocellular carcinoma with portal vein tumor thrombosis: a systematic review and meta-analysis. <i>Hpb</i> , 2017, 19, 659-666.	0.3	84
5	Chemotherapy for Surgically Resected Intrahepatic Cholangiocarcinoma. <i>Annals of Surgical Oncology</i> , 2015, 22, 3716-3723.	1.5	83
6	Modern perspectives on factors predisposing to the development of gallbladder cancer. <i>Hpb</i> , 2013, 15, 839-844.	0.3	59
7	Locally advanced pancreas cancer: Staging and goals of therapy. <i>Surgery</i> , 2018, 163, 1053-1062.	1.9	53
8	Distal splenorenal and temporary mesocaval shunting at the time of pancreatectomy for cancer: Initial experience from the Medical College of Wisconsin. <i>Surgery</i> , 2013, 154, 123-131.	1.9	49
9	Neoadjuvant chemoradiation with IMRT in resectable and borderline resectable pancreatic cancer. <i>Radiotherapy and Oncology</i> , 2014, 113, 41-46.	0.6	44
10	Portal Vein Resection. <i>Surgical Clinics of North America</i> , 2010, 90, 309-322.	1.5	41
11	Adjuvant therapy rates and overall survival in patients with localized pancreatic cancer from high Area Deprivation Index neighborhoods. <i>American Journal of Surgery</i> , 2021, 222, 10-17.	1.8	41
12	Survival of patients with borderline resectable pancreatic cancer who received neoadjuvant therapy and surgery. <i>Surgery</i> , 2019, 166, 277-285.	1.9	40
13	Techniques of Vascular Resection and Reconstruction in Pancreatic Cancer. <i>Surgical Clinics of North America</i> , 2016, 96, 1351-1370.	1.5	39
14	Critical steps for pancreaticoduodenectomy in the setting of pancreatic adenocarcinoma. <i>Journal of Surgical Oncology</i> , 2013, 107, 33-38.	1.7	38
15	Surgical resection versus ablation for hepatocellular carcinoma: a population-based analysis. <i>Hpb</i> , 2015, 17, 896-901.	0.3	34
16	Can response to treatment predict outcome in patients with metastatic pancreatic adenocarcinoma (MPAC)? <i>Journal of Clinical Oncology</i> , 2016, 34, 443-443.	1.6	31
17	Overall survival after resection of retroperitoneal sarcoma at academic cancer centers versus community cancer centers: An analysis of the National Cancer Data Base. <i>Surgery</i> , 2018, 163, 318-323.	1.9	29
18	Total Neoadjuvant Therapy for Operable Pancreatic Cancer. <i>Annals of Surgical Oncology</i> , 2021, 28, 2246-2256.	1.5	29

#	ARTICLE	IF	CITATIONS
19	The prognostic utility of baseline alpha-fetoprotein for hepatocellular carcinoma patients. <i>Journal of Surgical Oncology</i> , 2017, 116, 831-840.	1.7	27
20	Palliative Care Training in Surgical Oncology and Hepatobiliary Fellowships: A National Survey of Program Directors. <i>Annals of Surgical Oncology</i> , 2015, 22, 1181-1186.	1.5	23
21	Venous thromboembolism prophylaxis during neoadjuvant therapy for resectable and borderline resectable pancreatic cancer-Is it indicated?. <i>Journal of Surgical Oncology</i> , 2016, 114, 581-586.	1.7	23
22	Minimally invasive hepatectomy conversions: an analysis of risk factors and outcomes. <i>Hpb</i> , 2018, 20, 132-139.	0.3	23
23	External radiation or ablation for solitary hepatocellular carcinoma: A survival analysis of the SEER database. <i>Journal of Surgical Oncology</i> , 2017, 116, 307-312.	1.7	21
24	Impact of Neoadjuvant Chemoradiation on Pathologic Response in Patients With Localized Pancreatic Cancer. <i>Frontiers in Oncology</i> , 2020, 10, 460.	2.8	20
25	Multimodality Therapy in Patients With Borderline Resectable or Locally Advanced Pancreatic Cancer: Importance of Locoregional Therapies for a Systemic Disease. <i>Journal of Oncology Practice</i> , 2016, 12, 915-923.	2.5	19
26	Duplicate pancreas meets gastric duplication cyst: A tale of two anomalies. <i>International Journal of Surgery Case Reports</i> , 2013, 4, 735-739.	0.6	17
27	Two-Stage Hepatectomy for Bilateral Colorectal Liver Metastases: A Multi-institutional Analysis. <i>Annals of Surgical Oncology</i> , 2021, 28, 1457-1465.	1.5	17
28	Palliative interventions for hepatocellular carcinoma patients: analysis of the National Cancer Database. <i>Annals of Palliative Medicine</i> , 2017, 6, 26-35.	1.2	15
29	Distal splenorenal and mesocaval shunting at the time of pancreatectomy. <i>Surgery</i> , 2019, 165, 298-306.	1.9	14
30	RAS Mutation Status Confers Prognostic Relevance in Patients Treated With Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for Colorectal Cancer. <i>Journal of Surgical Research</i> , 2019, 240, 130-135.	1.6	13
31	Pancreatic ductal adenocarcinomas associated with intraductal papillary mucinous neoplasms (IPMNs) versus pseudo-IPMNs: relative frequency, clinicopathologic characteristics and differential diagnosis. <i>Modern Pathology</i> , 2022, 35, 96-105.	5.5	13
32	Characterizing indeterminate liver lesions in patients with localized pancreatic cancer at the time of diagnosis. <i>Abdominal Radiology</i> , 2018, 43, 351-363.	2.1	11
33	Intrahepatic cholangiocarcinoma and gallbladder cancer: distinguishing molecular profiles to guide potential therapy. <i>Hpb</i> , 2015, 17, 1119-1123.	0.3	10
34	Elective Regional Therapy Treatment for Hepatic Adenoma. <i>Annals of Surgical Oncology</i> , 2019, 26, 125-130.	1.5	10
35	Variant anatomy of the biliary system as a cause of pancreatic and peri-ampullary cancers. <i>Hpb</i> , 2020, 22, 1675-1685.	0.3	10
36	Replaced gastroduodenal artery: Added benefit of the "artery first" approach during pancreaticoduodenectomy—a case report. <i>International Journal of Surgery Case Reports</i> , 2016, 23, 93-97.	0.6	9

#	ARTICLE	IF	CITATIONS
37	5-FU/leucovorin, irinotecan, oxaliplatin (FOLFIRINOX) induction followed by chemoXRT in borderline resectable pancreatic cancer.. Journal of Clinical Oncology, 2012, 30, e14613-e14613.	1.6	9
38	The effect of prior upper abdominal surgery on outcomes after liver transplantation for hepatocellular carcinoma: An analysis of the database of the organ procurement transplant network. Surgery, 2018, 163, 1028-1034.	1.9	8
39	Effect of Donor Race-Matching on Overall Survival for African-American Patients Undergoing Liver Transplantation for Hepatocellular Carcinoma. Journal of the American College of Surgeons, 2019, 228, 245-254.	0.5	8
40	Neoadjuvant therapy for pancreatic cancer in patients older than age 75.. Journal of Clinical Oncology, 2014, 32, 287-287.	1.6	8
41	Additional Support for Neoadjuvant Therapy in the Management of Pancreatic Cancer. Annals of Surgical Oncology, 2015, 22, 1755-1758.	1.5	7
42	Primary Liver Cancer: An NCDB Analysis of Overall Survival and Margins After Hepatectomy. Annals of Surgical Oncology, 2020, 27, 1156-1163.	1.5	7
43	Comparison of overall survival in gallbladder carcinoma at academic versus community cancer centers: An analysis of the National Cancer Data Base. Journal of Surgical Oncology, 2020, 122, 176-182.	1.7	7
44	Outcomes of palliativeâ€”intent surgery in retroperitoneal sarcomaâ€”Results from the US Sarcoma Collaborative. Journal of Surgical Oncology, 2020, 121, 1140-1147.	1.7	7
45	Gallbladder Volvulus in a Patient with Type I Choledochal Cyst: A Case Report and Review of the Literature. Case Reports in Surgery, 2016, 2016, 1-6.	0.4	6
46	Outcomes of Elderly Patients Undergoing Curative Resection for Retroperitoneal Sarcomas: Analysis From the US Sarcoma Collaborative. Journal of Surgical Research, 2019, 233, 154-162.	1.6	6
47	Role of Molecular Profiling of Pancreatic Cancer After Neoadjuvant Therapy: Does it Change Practice?. Journal of Gastrointestinal Surgery, 2020, 24, 235-242.	1.7	6
48	Gross tumor size using the AJCC 8th ed. T staging criteria does not provide prognostic stratification for neoadjuvant treated pancreatic ductal adenocarcinoma. Annals of Diagnostic Pathology, 2020, 46, 151485.	1.3	6
49	Ablation approach for primary liver tumors: Periâ€”operative outcomes. Journal of Surgical Oncology, 2018, 117, 1493-1499.	1.7	5
50	Outcomes in metastatic pancreatic adenocarcinoma (MPAC) patients treated with FOLFIRINOX (FFX)/FOLFOX(FX) and gemcitabine + nab-paclitaxel (NabG).. Journal of Clinical Oncology, 2016, 34, 397-397.	1.6	5
51	Gallbladder carcinoma: An analysis of the national cancer data base to examine hispanic influence. Journal of Surgical Oncology, 2018, 117, 1664-1671.	1.7	4
52	Pancreaticoduodenectomy and Vascular Reconstruction. Surgical Oncology Clinics of North America, 2021, 30, 731-746.	1.5	4
53	A Novel Reconstruction Technique During Pancreaticoduodenectomy After Roux-En-Y Gastric Bypass: How I do It. Journal of Gastrointestinal Surgery, 2017, 21, 1186-1191.	1.7	3
54	Retroperitoneal lymphangi leiomyoma with lymph node involvement: A pathologic-radiologic correlation of a rare form of myomelanocytic tumor. Annals of Diagnostic Pathology, 2017, 27, 69-73.	1.3	3

#	ARTICLE	IF	CITATIONS
55	Locally advanced pancreatic cancer: staging, operability, and the importance of multimodality therapy. <i>Hepatobiliary Surgery and Nutrition</i> , 2020, 9, 497-500.	1.5	3
56	High neutrophil-lymphocyte ratio is not independently associated with worse survival or recurrence in patients with extremity soft tissue sarcoma. <i>Surgery</i> , 2020, 168, 760-767.	1.9	2
57	Detection of germline variants using expanded multigene panels in patients with localized pancreatic cancer. <i>Hpb</i> , 2020, 22, 1745-1752.	0.3	2
58	Association of decline in serum Ca19-9 after neoadjuvant therapy with improved survival among borderline resectable pancreatic cancer patients.. <i>Journal of Clinical Oncology</i> , 2013, 31, e15082-e15082.	1.6	2
59	Can the sequence of chemotherapy regimens influence outcome in patients with metastatic pancreatic adenocarcinoma (MPAC)?. <i>Journal of Clinical Oncology</i> , 2016, 34, 428-428.	1.6	2
60	Updates and new directions in the use of radiation therapy for the treatment of pancreatic adenocarcinoma: dose, sensitization, and novel technology. <i>Cancer and Metastasis Reviews</i> , 2021, 40, 879-889.	5.9	2
61	MEK-inhibitor (inh) and hydroxychloroquine (HCQ) in <i>KRAS</i> -mutated advanced pancreatic ductal adenocarcinoma (PDAC).. <i>Journal of Clinical Oncology</i> , 2022, 40, e16260-e16260.	1.6	2
62	Commentary: Venous resection and reconstruction at the time of pancreatectomy for cancer. <i>Surgery</i> , 2020, 168, 1058-1059.	1.9	1
63	Intraductal papillary squamous neoplasm of the pancreas: Cyto-histologic correlation of a novel entity. <i>Annals of Diagnostic Pathology</i> , 2020, 48, 151583.	1.3	1
64	Impact of KRAS alterations in pancreatic ductal adenocarcinoma (PDAC).. <i>Journal of Clinical Oncology</i> , 2021, 39, 4136-4136.	1.6	1
65	Microwave ablation for hepatic malignancies: A multi-institutional analysis.. <i>Journal of Clinical Oncology</i> , 2013, 31, 218-218.	1.6	1
66	Phase II clinical trial of biomarker-directed therapy for localized pancreatic cancer.. <i>Journal of Clinical Oncology</i> , 2013, 31, TPS4147-TPS4147.	1.6	1
67	Reconstructing the tumor microenvironment to unlock therapeutic options in pancreatic cancer.. <i>Journal of Clinical Oncology</i> , 2022, 40, 589-589.	1.6	1
68	The use of recombinant activated factor VII in trauma-associated hemorrhage with crush injury. <i>Journal of Trauma</i> , 2005, 59, 742-6.	2.3	1
69	Palliative Cytoreductive Surgery With or Without Hyperthermic Intraperitoneal Chemotherapy for Peritoneal Carcinomatosis: Is It Safe and Effective?. <i>Journal of Surgical Research</i> , 2022, 278, 31-38.	1.6	1
70	Should functional renal scans be obtained prior to upper abdominal IMRT for pancreatic cancer?. <i>Practical Radiation Oncology</i> , 2017, 7, e449-e455.	2.1	0
71	Impact of KRAS alterations in localized pancreatic cancer (PC).. <i>Journal of Clinical Oncology</i> , 2021, 39, 431-431.	1.6	0
72	Clinical outcomes in pancreatic ductal adenocarcinoma (PDAC) patients with underlying autoimmune disease (AID).. <i>Journal of Clinical Oncology</i> , 2021, 39, e16233-e16233.	1.6	0

#	ARTICLE	IF	CITATIONS
73	Does a common vascular origin confer similar prognosis to malignant tumors of the liver?. Journal of Clinical Oncology, 2012, 30, 186-186.	1.6	0
74	Are we justified in excluding combined hepatocellular-cholangiocarcinoma from transplantation?. Journal of Clinical Oncology, 2012, 30, 256-256.	1.6	0
75	Local control in resectable and borderline resectable pancreatic cancer (PCa) treated with preoperative chemoradiation using IMRT or chemotherapy alone.. Journal of Clinical Oncology, 2013, 31, 282-282.	1.6	0
76	Molecular profiling in gastric cancer: Examining potential targets for chemotherapy.. Journal of Clinical Oncology, 2014, 32, 131-131.	1.6	0
77	Chemotherapy for surgically resected intrahepatic cholangiocarcinoma: Influence of lymph node status on treatment efficacy.. Journal of Clinical Oncology, 2015, 33, 353-353.	1.6	0
78	Palliative care for hepatocellular carcinoma: Analysis of the National Cancer Data Base.. Journal of Clinical Oncology, 2016, 34, 390-390.	1.6	0
79	Rapid immunohistochemical analysis of pancreatic cytology from endoscopic ultrasound-guided fine-needle aspirates: A prospective clinical trial.. Journal of Clinical Oncology, 2016, 34, 400-400.	1.6	0
80	Overall survival and resection margin after hepatectomy for intrahepatic cholangiocarcinoma at academic cancer centers versus community cancer centers.. Journal of Clinical Oncology, 2016, 34, 339-339.	1.6	0
81	Radiotherapy for intrahepatic cholangiocarcinoma: An analysis of the National Cancer Database.. Journal of Clinical Oncology, 2016, 34, 379-379.	1.6	0
82	Two-stage hepatectomy for colorectal liver metastases: A multi-institutional retrospective review.. Journal of Clinical Oncology, 2017, 35, 351-351.	1.6	0
83	Should functional renal scans be obtained prior to upper abdominal radiation for pancreatic cancer?. Journal of Clinical Oncology, 2017, 35, 442-442.	1.6	0
84	Does hepatectomy approach influence transfusion? An analysis of the National Surgical Quality Improvement Program database.. Journal of Clinical Oncology, 2017, 35, 447-447.	1.6	0
85	Minimally invasive hepatectomy conversions: An analysis of outcomes.. Journal of Clinical Oncology, 2017, 35, 430-430.	1.6	0
86	Impact of age on genomic alterations associated with pancreatic ductal adenocarcinoma (PDAC).. Journal of Clinical Oncology, 2017, 35, 282-282.	1.6	0
87	Prognostic value of positron emission tomography and preoperative CA19-9 in patients treated on a prospective phase II trial of neoadjuvant therapy and surgery.. Journal of Clinical Oncology, 2017, 35, e15766-e15766.	1.6	0
88	A randomized, phase II clinical trial of preoperative stereotactic body radiation therapy versus conventionally fractionated chemoradiation for resectable, borderline-resectable, or locally advanced type a pancreatic adenocarcinoma.. Journal of Clinical Oncology, 2019, 37, TPS4167-TPS4167.	1.6	0
89	Utilization of somatic comprehensive genomic profiling (CGP) to identify patients (pts) with pancreatic cancer (PC) that harbor germline DNA damage repair (DDR) gene alterations.. Journal of Clinical Oncology, 2020, 38, 760-760.	1.6	0
90	Impact of CDKN2A/b status in pancreatic cancer (PC).. Journal of Clinical Oncology, 2020, 38, 759-759.	1.6	0

#	ARTICLE	IF	CITATIONS
91	Comprehensive genomic profiling (CGP) of fibrolamellar oncocytic hepatoma (FLO) and conventional hepatocellular carcinomas (HCC): An observational study.. Journal of Clinical Oncology, 2022, 40, 474-474.	1.6	0
92	Targeted therapy (TT) in patients with KRAS wildtype (WT) pancreatic ductal adenocarcinoma (PDAC) produces durable response.. Journal of Clinical Oncology, 2022, 40, 596-596.	1.6	0
93	Neoadjuvant radiation case volume and associated with margin-negative resection rates in patients with pancreatic cancer.. Journal of Clinical Oncology, 2022, 40, e16281-e16281.	1.6	0